Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
synthetic estrogen |
| gptkbp:affects |
gptkb:sex_hormone-binding_globulin
lipid metabolism estrogen receptor coagulation factors liver protein synthesis |
| gptkbp:ATCCode |
G03CA01
|
| gptkbp:CASNumber |
57-63-6
|
| gptkbp:category |
gptkb:Corticosteroid
oral contraceptive estrogen phenol secondary alcohol alkyne hormonal medication tertiary alcohol |
| gptkbp:chemicalFormula |
C20H24O2
|
| gptkbp:discoveredBy |
gptkb:Hans_Herloff_Inhoffen
1938 |
| gptkbp:eliminationHalfLife |
13–27 hours
|
| gptkbp:environmentalImpact |
endocrine disruptor
water pollutant |
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
17α-ethynylestradiol
|
| gptkbp:IUPACName |
(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
|
| gptkbp:meltingPoint |
182–184 °C
|
| gptkbp:MeSH_ID |
D004967
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
296.403 g/mol
|
| gptkbp:PubChem_CID |
5991
DB00977 CHEMBL1398 |
| gptkbp:routeOfAdministration |
oral
transdermal vaginal |
| gptkbp:sideEffect |
nausea
headache increased risk of blood clots |
| gptkbp:synonym |
ethinylestradiol
EE2 |
| gptkbp:UNII |
423D2T571U
|
| gptkbp:used_in |
oral contraceptives
|
| gptkbp:usedFor |
hormone replacement therapy
hormonal contraception |
| gptkbp:bfsParent |
gptkb:ethinyl_estradiol
|
| gptkbp:bfsLayer |
7
|